Author(s)

Natália Paseto Pilati¹, Maria Alexandrina Zanatta¹, Daniele Camila Maltauro¹, Gabrielle Behenck¹, Edimárlei Gonsales Valério^1,2, Fernanda Oliveira Castilhos^1,3, Eduardo Vettorazzi-Stuczynski³, Daniela Vanessa Vettori^1,2, Janete Vettorazzi^1,2*

¹Postgraduation Program in Health Sciences: Gynecology and Obstetrics (PPGGO), Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul, Brazil.
²Service of Gynecology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
³Hospital Geral de Caxias do Sul e Faculdade de Medicina da Universidade de Caxias do Sul, Caxias do Sul, Brazil.

A pregnant woman diagnosed with type 1 angioedema seeks care at a public hospital for planning the delivery. This report presents ways to prevent and manage an acute HAE crisis during childbirth and early postpartum without the availability of first-line medications, such as plasma-derived human C1-INH concentrate.

Hereditary Angioedema (HAE), C1-Inhibitor, High-Risk Pregnancy, Prophylaxis

Pilati, N. , Zanatta, M. , Maltauro, D. , Behenck, G. , Valério, E. , Castilhos, F. , Vettorazzi-Stuczynski, E. , Vettori, D. and Vettorazzi, J. (2021) Hereditary Angioedema in Pregnancy and Management without Recombinant Human C1-INH. Open Journal of Obstetrics and Gynecology, 11, 1470-1476. doi: 10.4236/ojog.2021.1111137.